Journal article
Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: A subgroup analysis of the CA209-538 clinical trial for rare cancers
O Klein, D Kee, B Markman, M Michael, C Underhill, MS Carlino, L Jackett, C Lum, C Scott, A Nagrial, A Behren, JY So, J Palmer, J Cebon
Clinical Cancer Research | Published : 2020
Abstract
Purpose: Combination immunotherapy with anti-CTLA-4 and anti-PD-1 blockade has demonstrated significant clinical activity across several tumor types. Neuroendocrine tumors (NET) are a heterogeneous group of rare tumors with limited treatment options. CA209-538 is a clinical trial of combination immunotherapy with ipilimumab and nivolumab in rare cancers, including advanced NETs. Patients and Methods: CA209-538 is a prospective multicenter clinical trial in patients with advanced rare cancers. Patients received treatment with nivolumab at a dose of 3 mg/kg and ipilimumab at 1 mg/kg every three weeks for four doses, followed by nivolumab 3 mg/kg every two weeks and continued for up to 96 weeks..
View full abstractGrants
Funding Acknowledgements
The study received funding and drug support from Bristol-Myers Squibb; funding support was also provided in part by a grant from the Commonwealth of Australia, Department of Health Accelerated Research Program. A. Behren is supported by a fellowship from the Department of Health and Human Services acting through the Victorian Cancer Agency.